The reform business wanted, minus the part that makes it stick
The Gene Technology Bill reaches its second reading in Parliament this week, and on the science it is exactly what much of the primary and biotech sector has been asking for. New Zealand’s existing framework, the Hazardous Substances and New Organisms Act 1996, is one of the most restrictive regimes in the OECD, and it has delivered almost no genetically modified organism releases under current law. The bill replaces it with a risk-proportionate authorisations model covering gene editing for crops, seeds, emissions mitigation and productivity, ending New Zealand’s de facto GMO-free status.
The NZ Initiative argued in its 2025 submission that the HSNO regime has stalled productivity and made R&D unnecessarily difficult and costly. BioTechNZ’s February 2025 submission backed modernising the outdated framework. On the case for reform, the business argument is strong and the direction is right.
But the way it is being pushed through creates a different kind of risk, and it is the kind investors and exporters should care about most.
The Australian model, with the ethics module removed
The bill closely mirrors Australia’s regulatory system, with one glaring omission. As a Newsroom commentary published this week sets out, it has no equivalent to Australia’s Gene Technology Ethics and Community Consultative Committee. The bill builds pathways to assess risk and issue licences, but no dedicated mechanism for the broader ethical questions the technology raises.
New Zealand once had that mechanism. Toi te Taiao, the Bioethics Council, was established after the Royal Commission on Genetic Modification in 2001 to help regulators and the public think through the cultural, ethical and spiritual dimensions of emerging technology. It was disestablished in 2009, and decisions since have been framed as technical matters for scientists and regulators. But debates about kaitiakitanga, Te Tiriti obligations and acceptable risk are debates about values, and scientific evidence can inform them without resolving them.
The gap was laid bare at select committee on 5 March 2025, when then-science minister Shane Reti was asked directly about environmental ethics. His answer, per the same Newsroom analysis, was that he did not know the answer and it was not part of his current thinking. When the minister responsible cannot address a foundational question, the framework has a hole in it.
Why the coalition nearly blew up over it
This is not an abstract academic concern. It is why the bill’s passage has been so fraught. In October 2025, coalition partners demanded late changes over bioethics oversight, environmental protections and regulatory frameworks, threatening the government’s unified position. NZ First signalled it would withhold support unless stronger oversight and annual reporting aligned with Australia’s approach were added.
The Health Select Committee’s October 2025 report recommended the bill proceed but attached nearly 15 pages of changes. Government ministers were still being questioned in October 2025 over how they would resolve competing demands, and most parties oppose the bill in its current form. The second reading proceeding does not mean the bill is safe. It means the hard negotiations are about to go public.
The number that should anchor every boardroom conversation
For business, the stakes are quantifiable. The bill’s own commentary cites NZIER analysis finding that environmental release of GMOs could reduce primary sector exports by up to $10-20 billion annually if major trading partners or premium food markets react badly to a status change. That is not a fringe estimate. It is the market access risk sitting behind the entire reform.
A July 2025 Newsroom analysis warned the bill ignores global regulatory standards at producers’ peril, and the Law Society’s 2025 submission flagged that weak ethical frameworks create legal and compliance risk, the kind of downstream uncertainty that makes investors nervous. A July 2025 analysis in The Conversation reached the same conclusion, that a truly independent regulator is vital for the system to do more good than harm.
Durable consent is the actual product
The market does not need the bill to be bolder or more timid. It needs certainty. A reform passed without durable public consent invites legal challenge, market backlash, or reversal under a future government, and any of those outcomes is worse for agri-exporters than a well-designed ethics function ever could be. New Zealand had that function in Toi te Taiao and cut it in 2009. Rebuilding it, as Australia has, is not bureaucratic overreach. It is the price of a reform that holds, and the cost of skipping it could run to billions.
Sources
- NZ gene tech law rewrite has a gaping ethics gap (2026-07-21)
- Late changes demanded to gene tech bill, splitting coalition (2025-10-14)
- Govt questioned over its plans to deal with gene tech bill concerns (2025-10-20)
- Radical genetech bill ignores global standards at Kiwi producers’ peril (2025-07-18)
- NZ First to withhold support for Gene Tech bill unless major changes are made
- Political parties negotiate controversial Gene Technology Bill, as progress stalls
- NZ’s gene technology reform carries benefits and risks (2025-07-21)
- BioTechNZ Submission – Gene Regulations Bill (2025-02)
- Gene Technology Bill – Law Society Submission (2025)
- Gene Technology Bill Submission – NZ Initiative (2025)